Code | CSB-RA019112A118phHU |
Size | US$210 |
Order now | |
Image | |
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
WB | 1:500-1:5000 |
The vectors expressing anti-PXN antibody were constructed as follows: immunizing an animal with a synthesized peptide derived from human Phospho-PXN (Y118), isolating the positive splenocyte and extracting RNA, obtaining DNA by reverse transcription, sequencing and screening PXN antibody gene, and amplifying heavy and light chain sequence by PCR and cloning them into plasma vectors. After that, the vector clones were transfected into the mammalian cells for production. The product is the recombinant PXN antibody. Recombinant PXN antibody in the culture medium was purified using affinity-chromatography. It can react with PXN protein from Human and is used in the ELISA, WB.
PXN encodes a cytoskeletal protein involved in the actin-membrane attachment at sites of cell adhesion to the extracellular matrix. According to some studies, PXN may have the following characteristics.
The MBNL3 splicing factor increases the expression of PXN through alternative splicing of lncRNA-PXN-AS1 and promotes hepatocellular carcinoma. Nobiletin inhibits angiogenesis by modulating Src/FAK/STAT3-mediated signaling in ER+ breast cancer cells via PXN. ETV4 overexpression promotes the progression of non-small cell lung cancer by upregulating the transcription of PXN and MMP1. Pan-cancer analysis reveals immunological roles and prognostic potential of PXN in human cancers.
There are currently no reviews for this product.